---
title: "Egetis Wins FDA Priority Review for Emcitate as EU Launch Gathers Pace"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284499167.md"
description: "Egetis Therapeutics AB has received FDA Priority Review for its New Drug Application for Emcitate (tiratricol) to treat MCT8 deficiency, with a target action date of September 28, 2026. The company is also advancing its EU commercialization efforts, reporting a 9% revenue increase in Europe. Egetis has strengthened its intellectual property with a U.S. composition patent expected to be valid through 2045. Despite a quarterly loss, the company raised SEK 350 million through a share issue and is focusing on pricing and reimbursement processes in Germany, Italy, and France."
datetime: "2026-04-29T05:37:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284499167.md)
  - [en](https://longbridge.com/en/news/284499167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284499167.md)
---

# Egetis Wins FDA Priority Review for Emcitate as EU Launch Gathers Pace

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from Egetis Therapeutics AB ( (SE:EGTX) ) is now available.

Egetis Therapeutics reported that the U.S. FDA has accepted and granted Priority Review to its New Drug Application for Emcitate (tiratricol) to treat MCT8 deficiency, setting a PDUFA target action date of September 28, 2026 and indicating it does not currently plan an advisory committee meeting. The company also strengthened its intellectual property with a Notice of Allowance for a U.S. composition patent for Emcitate expected to be Orange Book-listable through 2045, while advancing EU commercialization, increasing European Emcitate revenue 9% at constant exchange rates, and bolstering its balance sheet via an oversubscribed SEK 350 million directed share issue despite posting a quarterly loss.

Operationally, Egetis highlighted continued rollout of Emcitate in Europe, led by Germany where managed access patients have transitioned to commercial product and physician engagement and education initiatives are ongoing. The company is progressing pricing and reimbursement processes in Germany, Italy and France, maintaining modest net revenue growth and cash reserves of MSEK 142.5 as it invests in clinical, regulatory and commercial activities ahead of a potential U.S. launch and possible monetization of a Priority Review Voucher related to Emcitate’s rare pediatric disease status.

**More about Egetis Therapeutics AB**

Egetis Therapeutics AB is a specialty pharmaceutical company focused on developing and commercializing treatments for rare endocrine and genetic diseases. Its lead product, Emcitate (tiratricol), targets MCT8 deficiency, a rare thyroid hormone transport disorder, with a key market focus on the U.S. and European markets, including Germany and Italy.

**Average Trading Volume:** 861,323

**Technical Sentiment Signal:** Buy

**Current Market Cap:** SEK2.34B

See more data about EGTX stock on TipRanks’ Stock Analysis page.

## Related News & Research

- [Sinclair’s Largest Promotion of the Year Is Back and Too Big for Just One Day | DINO Stock News](https://longbridge.com/en/news/288085239.md)
- [Wheat Falls into the End of the Month](https://longbridge.com/en/news/288124795.md)
- [OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | OSRH Stock News](https://longbridge.com/en/news/287777430.md)
- [How have interest rate expectations changed after this week's event?](https://longbridge.com/en/news/288104400.md)
- [EU Commission agrees to unlock €16.4 billion for Hungary](https://longbridge.com/en/news/288071155.md)